Sublimity Therapeutics Closes US$64 Million Financing to Fund Development of New Oral Ulcerative Colitis Drug Candidate

Orally delivered soluble formulation of cyclosporine represents promising new treatment option for patients with moderate to severe ulcerative colitis DUBLIN Ireland May 22 2018 GLOBE NEWSWIRE Sublimity Therapeutics Limited formerly Sigmoid Pharma ...